文献速递心力衰竭与心肌病

心力衰竭的蛋白质组学特征与左心室射血分数的关系

Proteomic Signatures of Heart Failure in Relation to Left Ventricular Ejection Fraction.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

该研究采用基于适配体的高通量蛋白质组学技术(SOMAscan)检测华盛顿大学心力衰竭注册研究中年龄和性别匹配的不同左心室射血分数(LVEF)组心力衰竭患者的血液蛋白质组。研究发现射血分数降低、中间值和保留的心力衰竭患者具有独特的循环蛋白变异,反映了不同的病理生理学;射血分数恢复的中间值患者蛋白质组特征更接近射血分数保留者;缺血性与非缺血性心力衰竭的蛋白质组特征也存在显著差异。

要点

  • 不同LVEF类别的心力衰竭患者具有独特的循环蛋白质组特征。
  • LVEF恢复的HFmrEF患者蛋白质组更接近HFpEF而非HFrEF。
  • 缺血性与非缺血性心力衰竭的蛋白质组特征存在显著差异。

核心结论

  • 高通量多重蛋白质组学检测联合LVEF临床评估可能更准确地识别心力衰竭的临床表型。

研究设计与样本

  • 研究使用基于适配体的高通量蛋白质组学技术(SOMAscan)检测华盛顿大学心力衰竭注册研究中年龄和性别匹配的不同LVEF组心力衰竭患者的血液蛋白质组。
  • LVEF分组为HFrEF(LVEF<40%)、HFmrEF(LVEF 40%~50%)和HFpEF(LVEF>50%)。

主要发现

  • HFrEF、HFmrEF和HFpEF患者的循环蛋白存在独特变异,反映了不同的病理生理学。
  • 生物信息学分析显示HFrEF、HFpEF或HFmrEF患者存在各自独特的生物学主题。
  • LVEF改善的HFmrEF患者与LVEF未改善的HFmrEF患者之间存在显著差异,LVEF恢复者更接近HFpEF而非HFrEF。
  • 缺血性与非缺血性心力衰竭患者的蛋白质组特征存在显著差异。

临床怎么用

  • 在临床评估LVEF的基础上,可考虑采用高通量多重蛋白质组学检测以更准确地识别心力衰竭的临床表型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a growing recognition of the inherent limitations of the use of the left ventricular ejection fraction (LVEF) to accurately phenotype patients with heart failure (HF). OBJECTIVES: The authors sought to identify unique proteomic signatures for patients with HF with reduced ejection fraction (HFrEF), HF with a midrange LVEF (HFmrEF), and HF with preserved ejection fraction (HFpEF), as well as to identify molecular differences between patients with ischemic and nonischemic HF. METHODS: We used high-content aptamer-based proteomics technology (SOMAscan) to interrogate the blood proteome of age- and sex-matched patients with HF within different LVEF groups. RESULTS: Within the Washington University Heart Failure Registry, we identified age/sex-matched patients within 3 LVEF categories: HFrEF (LVEF <40%), HFmrEF (LVEF 40% to 50%), and HFpEF (LVEF >50%). We found that patients with HFrEF, HFmrEF, and HFpEF had unique variations in circulating proteins that reflected distinct biological pathophysiologies. Bioinformatics analysis revealed that there were biological themes that were unique to patients with HFrEF, HFpEF, or HFmrEF. Comparative analyses of patients with HFmrEF with improved LVEF and patients with HFmrEF with unchanged LVEF revealed marked differences between these 2 patient populations and indicated that patients with recovered LVEF are more similar to patients with HFpEF than to patients with HFrEF. Moreover, there were marked differences in the proteomic signatures of patients with ischemic and nonischemic HF. CONCLUSIONS: Viewed together, these findings suggest that it may be possible to use high-content multiplexed proteomics assays in combination with the clinical assessment of LVEF to more accurately identify clinical phenotypes of patients with HF.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Adamo L, Yu J, Rocha-Resende C, et al. Proteomic Signatures of Heart Failure in Relation to Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2020. PMID: 33092734. doi:10.1016/j.jacc.2020.08.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。